期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

Prostate-specific antigen doubling time and response to cabazitaxel in a hormone-resistant metastatic prostate cancer patient

Prostate-specific antigen doubling time and response to cabazitaxel in a hormone-resistant metastatic prostate cancer patient
在线阅读 下载PDF
导出
摘要 We report a case of metastatic castration-resistant prostate cancer, who received prior treatment with docetaxel and was then given cabazitaxel as salvage therapy. The patient was monitored by prostate-specific antigen doubling time and prostate-specific antigen absolute value. The prostate-specific antigen doubling time was found to be a good response predictor in the patient. We report a case of metastatic castration-resistant prostate cancer, who received prior treatment with docetaxel and was then given cabazitaxel as salvage therapy. The patient was monitored by prostate-specific antigen doubling time and prostate-specific antigen absolute value. The prostate-specific antigen doubling time was found to be a good response predictor in the patient.
作者 Marwan Ghosn Alain Dagher Fadi El-Karak
机构地区 Hematology-Oncology Department
出处 《The Journal of Biomedical Research》 CAS CSCD 2015年第5期420-422,共3页 生物医学研究杂志（英文版）
关键词 prostate-specific antigen doubling time prostate cancer CABAZITAXEL DOCETAXEL prostate-specific antigen, doubling time, prostate cancer, cabazitaxel, docetaxel
分类号 R737.25 [医药卫生—肿瘤]
  • 相关文献

参考文献9

  • 1de Bono JS, Oudard S, Ozguroglu M, et al. TROPIC Investigators. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial[J]. Lancet, 2010,376(9747):1147-1154.
  • 2Vickers AJ, Savage C, O'Brien MF, et al. Systematic review of pretreatment prostate-specific antigen velocity and doubling time as predictors for prostate cancer[J]. J Clin Oncol, 2009,27(3):399403.
  • 3O'Brien MF, Cronin AM, Fearn PA, et al. Pretreatment prostate-specific antigen (PSAyvelocity and doubling time are associated with outcome but neither improves predic- tion of outcome beyond pretreatment PSA alone in patients treated with radical prostatectomy[J]. J Clin Oncol, 2009,27(22):3591-3597.
  • 4Ulmert D, Serio AM, O'Brien MF, et al. Long-term pre- diction of prostate cancer: PSA velocity is predictive but does not improve the predictive accuracy of a single PSA measurement 15 years or more before cancer diagno- sis in a large, representative, unscreened population[J]. J Clin Oncol, 2008,26(6):835-841.
  • 5Thomsen FB, Christensen I1, Brasso K, et al. Prostate- specific antigen doubling time as a progression criterion in an active surveillance programme for patients with loca- lised prostate cancer[J]. BJU lnt, 2014,113(5b):E98-105.
  • 6Sengupta S, Myers RP, Slezak JM, et al. Preoperative prostate specific antigen doubling time and velocity are strong and independent predictors of outcomes following radical prostatectomy[J]. J Urol, 2005,174(6):2191-2196.
  • 7D'Amico AV, Chen MH, Roehl KA, et al. Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy[J]. N Engl J Med, 2004,351(2): 125-135.
  • 8Khatami A, Aus G, Damber JE, et al. PSA doubling time predicts the outcome after active surveillance in screening- detected prostate cancer: Results from the European ran- domized study of screening for prostate cancer, Sweden section[J]. Int J Cancer, 2007,120(1):170-174.
  • 9Elshafei A, Li YH, Hatem A, et al. The utility of PSA velo- city in prediction of prostate cancer and high grade cancer after an initially negative prostate biopsy[J]. Prostate, 2013,73:1796-1802.
The Journal of Biomedical Research
2015年 第5期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部